West Pharmaceutical Services (WST) Q1 2024 Earnings
West Pharmaceutical Services reported Q1 2024 revenue of $695.4M, beat analyst consensus of $670.6M by $24.8M. Diluted EPS came in at $1.56, beat the $1.26 consensus by $0.30. West Pharmaceutical Services reports across 2 business segments, led by Proprietary Products and Contract-Manufactured Products.
Financial Snapshot
Trailing eight quarters through Q1 2024
Q1 2024 Earnings FAQ
Common questions about West Pharmaceutical Services's Q1 2024 earnings report.
West Pharmaceutical Services (WST) reported Q1 2024 earnings on April 25, 2024 before market open.
West Pharmaceutical Services reported revenue of $695.4M and diluted EPS of $1.56 for Q1 2024.
Revenue beat the consensus estimate of $670.6M by $24.8M. EPS beat the consensus estimate of $1.26 by $0.30.
You can read the 10-Q periodic report (0000105770-24-000031) directly on SEC EDGAR. The filing index links above go to sec.gov.